Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lifted by Sheets Smith Wealth Management

Sheets Smith Wealth Management increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 85.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 42,701 shares of the biopharmaceutical company's stock after purchasing an additional 19,641 shares during the period. Sheets Smith Wealth Management's holdings in Gilead Sciences were worth $3,459,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GILD. Clearbridge Investments LLC boosted its holdings in shares of Gilead Sciences by 179.0% during the third quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company's stock worth $340,526,000 after purchasing an additional 2,915,141 shares during the period. abrdn plc grew its stake in Gilead Sciences by 89.0% in the fourth quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company's stock valued at $304,930,000 after purchasing an additional 1,772,887 shares in the last quarter. International Assets Investment Management LLC acquired a new position in Gilead Sciences in the 4th quarter worth about $133,584,000. AEGON ASSET MANAGEMENT UK Plc purchased a new stake in shares of Gilead Sciences during the 4th quarter worth about $63,971,000. Finally, Van ECK Associates Corp lifted its holdings in shares of Gilead Sciences by 18.3% during the 3rd quarter. Van ECK Associates Corp now owns 4,534,839 shares of the biopharmaceutical company's stock valued at $339,841,000 after buying an additional 702,342 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Gilead Sciences stock traded down $0.55 during mid-day trading on Friday, reaching $64.78. The company had a trading volume of 7,822,720 shares, compared to its average volume of 7,345,331. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08. The firm has a market cap of $80.66 billion, a price-to-earnings ratio of 179.94, a PEG ratio of 1.30 and a beta of 0.22. The company has a 50 day moving average of $70.55 and a 200-day moving average of $75.78. Gilead Sciences, Inc. has a 52 week low of $64.33 and a 52 week high of $87.86.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion during the quarter, compared to analysts' expectations of $6.36 billion. During the same quarter last year, the company earned $1.37 earnings per share. The firm's revenue was up 5.3% on a year-over-year basis. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 3.74 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.75%. Gilead Sciences's payout ratio is 855.56%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on GILD. Maxim Group reduced their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a "buy" rating for the company in a research note on Wednesday. TD Cowen decreased their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a "buy" rating for the company in a report on Friday, April 26th. Wells Fargo & Company reduced their price target on Gilead Sciences from $84.00 to $77.00 and set an "equal weight" rating for the company in a research report on Monday, March 4th. Barclays lowered their price objective on Gilead Sciences from $80.00 to $76.00 and set an "equal weight" rating on the stock in a report on Monday, April 29th. Finally, Morgan Stanley reduced their target price on Gilead Sciences from $80.00 to $78.00 and set an "equal weight" rating for the company in a report on Friday, April 26th. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of "Hold" and a consensus target price of $83.69.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.